Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?

Eli Lilly and Company’s (LLY) shares dipped almost 5% on Monday after rival Novo Nordisk (NVO) announced disappointing data from a late-stage study on next-generation obesity drug, CagriSema.Top-line data from the phase III REDEFINE 2 study on Novo Nordisk’s CagriSema showed that treatment with the drug led to a weight loss of 15.7% after 68 weeks compared to a reduction of 3.1% with placebo in people with obesity and type II diabetes. However, the weight loss of 15.7% fell short of expectations as investor ...